Industry News
Genesis beefs up strategic development with new hiring
New Zealand's Genesis Research and Development Corporation has persuaded long-serving director Dr Douglas Williams to join the company as head of its new strategic development unit, as part of its plan to make hay while it waits for the sun to rise again on the biotech industry. [ + ]
Global gene guild gets the buzz on pesticide resistance
It seems that globalisation works for genes too. Over the past half century, a global guild of the geneticist's favourite fruit fly, Drosophila melanogaster, has been using science's global networks to smuggle a souped-up, multi-purpose survival kit to its six-legged subscribers. [ + ]
Stem cell Bill moves to the Senate
The stage has been for a final Senate debate on a Bill permitting research on embryonic human stem cells following the legislation's passage by a three-to-one margin in the House of Representatives. [ + ]
Axon aiming to seal J&J deal
Listed drug discovery instrumentation maker Axon Instruments is aggressively pursuing final-stage development of an ion channel drug discovery platform in collaboration with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD). [ + ]
New ovarian cancer test developed
An improved test for ovarian cancer has been developed by Melbourne researchers. The team from Prince Henry's Institute of Medical Research and Monash University's Department of Obstetrics and Gynaecology has developed a test that, in conjunction with the standard test, can detect 90-95 per cent of cancers. [ + ]
Iatia MD Cussinet resigns
The resignation of Iatia managing director Philippe Cussinet will not impact the growth of the company, according to CEO Brian Powell. [ + ]
Local scientists slam UK anti-GM report
Scientists have criticised a new report -- Seeds of doubt: North American farmers' experiences of GE crops -- released by the Soil Association, the UK's main campaigning organisation for organic farming. [ + ]
Melbourne Uni teams up with US company for Alzheimer's drugs
Looking to develop new methods to test Alzhiemer's drugs, US-based company Axonyx has signed an agreement with University of Melbourne's Dr David Small. [ + ]
Melbourne researchers uncover new diabetes syndrome
A Melbourne University study has thrown new light on a dangerous complication of insulin-dependent diabetes called hypoglycaemic unawareness, which can cause diabetics to lapse into an insulin-induced coma. [ + ]
Xenografting success brings hope for animal conservation
Endangered species could now live forever following research that shows an animal's ovarian tissue grafted onto tissues in another species can produce healthy live young.
[ + ]Funds lagging for new stem cell centre
A skeleton administrative staff is at work on the $43.5 million National Stem Cell Centre even though Federal government has yet to sign a deed of agreement for the controversial research institute. [ + ]
Promics progresses with BIF money
A $216,800 government grant to Promics is the latest piece of good news for the young biotech and its anti-inflammatory drug candidate PMX53. [ + ]
AusBiotech to probe industry's insurance woes
Rumours that biotechnology companies are finding it hard to renew professional indemnity insurance policies have led industry association AusBiotech to investigate the potential for problems. [ + ]
VC tax reforms could assist biotech
The Federal government is implementing changes to venture capital tax structures which carry positive long-term implications for biotech companies seeking risk capital. [ + ]
GM cotton gains Australian approval for commercial release
The OGTR has approved Monsanto's application for commercial release of its GM cotton varieties in some areas. [ + ]